IGHE and immunoglobulin G4-related sclerosing disease: In a prospective trial of rituximab in IgG4-RD, higher baseline levels in serum IgG4, IgE and blood eosinophil concentrations predicted greater risk of IgG4-RD relapse and shorter time to relapse, rendering monitoring of these values significant [75].